SOURCE: Global Equity Reporter

June 01, 2011 09:00 ET

New Change Ahead for Biopharmaceuticals -- Insight on Elite Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd.

BEIJING--(Marketwire - Jun 1, 2011) - Today, www.GlobalEquityReporter.com announced its research report highlighting Elite Pharmaceuticals, Inc. (OTCBB: ELTP) and Taro Pharmaceutical Industries Ltd. (PINKSHEETS: TAROF). Full report download is available at www.GlobalEquityReporter.com/access.php.

Biotech is enabling creation of new drugs at a faster pace than the traditional pharmaceutical model and some believe that after a decade of mediocre performance it is approaching an inflection point. Companies are much more conducive to focusing on productivity and the sector is showing signs of being back to top growth by 2013 due to the opportunity emerging markets have created.

Global Equity is reporting on Elite Pharmaceuticals, Inc. for its position as a specialty pharmaceutical company principally engaged in the development and manufacture of oral, controlled-release products, using technology. The Company has two products: Lodrane 24 and Lodrane 24D, being sold commercially. It also has an approved generic methadone product developed with its partner. The PharmaNetwork. Elite manufactures two once-daily allergy products, Lodrane 24 and Lodrane 24D, that were co-developed with its partner, ECR Pharmaceuticals (ECR). The full report and profile on Elite Pharmaceuticals, Inc. (OTCBB: ELTP) is available here: www.GlobalEquityReporter.com/get.PDF.1824.php.

Global Equity Reporter brings Taro Pharmaceutical Industries to light for its focus on developing, manufacturing and marketing prescription and over-the-counter (OTC) pharmaceutical products primarily in the United States, Canada and Israel. It also develops and manufactures active pharmaceutical ingredients (APIs) primarily for use in its finished dosage form products. Its primary areas of focus include topical creams and ointments, liquids, capsules and tablets, mainly in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. The full report and profile on Taro Pharmaceutical Industries Ltd. (PINKSHEETS: TAROF) is available here: www.GlobalEquityReporter.com/get.PDF.1937.php.

About Global Equity Reporter
Global Equity Reporter is a premier source for microcap research -- providing a wide range of due diligence and investment insight on stocks all over the market Global Equity Reporter's primary focus is to alert our valued subscribers to small cap and microcap companies poised for explosive movement in the market. As every investor knows, timing in the market is critical, and that's where Global Equity Reporter delivers. We report potential market opportunity to our members before the same situation grows to become strong market momentum, enabling our members to see strong market growth by delivering information before the crowd.

Contact Information